Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: 0.00 (0.00%)
Spread: 0.01 (0.011%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 90.79
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Drugs group Sanofi makes Olympic jump in rebrand bid

Wed, 10th Jan 2024 06:00

LONDON, Jan 10 (Reuters) - Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

The 2024 Games has gained other new partners from the host nation France, including luxury goods giant LVMH and supermarket group Carrefour.

Sanofi, which some estimate is spending tens of millions of euros on the Paris Games, says it has sometimes struggled to convince prospective young data managers and data scientists that a pharmaceuticals company is a "cool" place to work.

"We're using the Olympics to show that we are," said Josep Catlla, head of corporate affairs at Sanofi, which is also supporting popular French breakdancer Dany Dann.

The median age of Olympics viewers is rising, data firms have said, and the International Olympic Committee has been trying to drum up Gen Z and Millennial interest through social media campaigns as younger audiences move away from TV, and by introducing newer sports such as breakdancing and skateboarding.

Sanofi is financially supporting 14 individuals in Paris, including British Paralympic swimmer Ellie Challis, in a team comprising an equal number of men and women, and an equal number of Olympic and Paralympic athletes.

"We're playing into the diversity aspect," Catlla said.

Sanofi is also bringing more than 8,000 employees to the Games as volunteers or through internal rewards programmes.

It declined to give details of how much it is spending, saying it is "putting as much money back into our employees as we have paid to the games organizer".

Olympic sponsorship fees alone are between 80 million euros ($87.5 million) and 150 million euros, French media reports have said.

Nick Blenkarne, head of strategy at branding agency Imagination in London, said Sanofi is likely to be looking at its "expensive" sponsorship through several lenses.

These include how it could change the way consumers perceive the company, how it could attract business customers through hospitality programmes, and how it could widen its appeal.

"Positioning yourself as an organisation that wants to do good in the world is always going to be good for attracting new talent," said Blenkarne, whose firm has worked with Samsung and Hyundai at previous Olympic Games.

"Big events like the Olympics and the World Cup are proven to move the needle when it comes to brand perception," he added, noting that brands like Cisco and Visa have also been unlikely, but long-time, Olympic sponsors.

'EXCEPTION'

Catlla said Sanofi, which is one of the biggest makers of vaccines and anti-inflammation treatments and normally sponsors events relating to diseases or patient communities, has made an "exception" for the Olympics partly because they are in Paris.

"We're not in sport and culture or music or other things consumer goods companies do," he added.

The Olympic Games have traditionally seen one-off sponsors from host nations that are not part of the sports or consumer industries. Partners of the Tokyo 2020 Olympics included firms such as Tokyo Gas, Japan Airlines, Nomura and Tanaka Holdings.

Sanofi did not comment when asked whether the French government had suggested it sponsor the Paris Olympics

It remains to see whether Sanofi's sponsorship will move the dial for investor perceptions, after several years of mixed financial results.

"Maybe (the Olympics) is another opportunity to change minds on the company's innovation engine," said Terence McManus, a fund manager with a focus on healthcare at Switzerland's Bellevue Asset Management, which is a Sanofi shareholder.

In October, Sanofi abandoned its 2025 profit target under a plan to list its consumer healthcare business and spend more on testing innovative drugs, wiping 20 billion euros ($22 billion) off its market value.

Sanofi CEO Paul Hudson, who joined four years ago with a mandate to turn the company around, has faced setbacks including the failure of breast cancer pill amcenestrant and losing out in the race for a COVID-19 vaccine.

"I think this (the Olympics) is maybe part of a wider cultural change that the new management team has been at the head of since various members joined between 2019 and now," said Tom Lemaigre, European equities portfolio manager at Sanofi investor Janus Henderson.

"I don't know how sponsoring the Olympics can be seen as a force for bad. They're about unity and competition -- people performing at the highest level."

Lemaigre noted that to the general public and potential employees there could be "a kind of cachet", but "sponsoring a big event like this in and of itself isn't going to change an investor's perception on the company." ($1 = 0.9140 euros) (Reporting by Richa Naidu and Ludwig Berger. Additional reporting by Helen Reid; Editing by Matt Scuffham and Alexander Smith)

More News
4 Nov 2022 07:00

Sanofi, Astra win EU approval for prevention of infant RSV

Nov 4 (Reuters) - The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.

Read more
2 Nov 2022 15:47

New GSK maintains strong start, but Zantac litigation looms large

Q3 profit, sales beat expectations

*

Read more
29 Sep 2022 11:44

Oddo BHF flags European pharma's attractive growth profile, prefers Novo Nordisk, AstraZeneca

Read more
26 Sep 2022 15:22

GSK selects Burberry's Brown as its first female CFO

Brown to join GSK in April

*

Read more
20 Sep 2022 08:58

Haleon believes it is not liable for any potential Zantac liabilities

LONDON, Sept 20 (Reuters) - Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.

Read more
20 Sep 2022 07:14

Haleon rejects Zantac indemnification requests from GSK, Pfizer

LONDON, Sept 20 (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Read more
5 Sep 2022 15:24

Sanofi sees EU regulatory decision on its COVID booster in weeks

BRUSSELS, Sept 5 (Reuters) - The European Union's drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.

Read more
30 Aug 2022 17:14

European stocks fall for third day as rate hike, recession fears grow

Aug 30 (Reuters) - European shares ended lower on Tuesday, failing to shrug off fears of higher interest rates amid a burgeoning energy crisis and looming recession.

Read more
17 Aug 2022 18:10

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Read more
17 Aug 2022 17:22

European shares slip on inflation worries, Germany leads fall

Aug 17 (Reuters) - European shares slid on Wednesday and bond yields rallied after a sharp rise in UK inflation brought the spotlight back to more monetary tightening amid data which showed euro zone economic growth was slightly less robust in the second quarter.

Read more
17 Aug 2022 15:15

Plaintiff in first Zantac lawsuit set for trial drops case

Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Read more
17 Aug 2022 08:21

GSK shares ease after plaintiff in first Zantac lawsuit drops case

LONDON, Aug 17 (Reuters) - Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case.

Read more
15 Aug 2022 22:17

UK first to approve Omicron COVID shot with Moderna nod

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

Read more
12 Aug 2022 17:17

European shares rise as healthcare, leisure stocks gain

Aug 12 (Reuters) - European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.

Read more
12 Aug 2022 11:00

Drugmakers' shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi , Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.